News related to Januvia (Sitagliptin) and/or conditions it is approved for
Another SGLT2 Inhibitor, Ertugliflozin, Meets Goals in Two Trials Source: Medscape Diabetes & Endocrinology Headlines [2017.09.25] In two phase 3 trials, the SGLT2 inhibitor ertugliflozin for the treatment of type 2 diabetes that is uncontrolled with metformin alone or with sitagliptin demonstrated safety and efficacy at 52 weeks. Medscape Medical News
|